Department of Medicine and Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada M5G 2A8.
Am J Physiol Renal Physiol. 2012 Mar 15;302(6):F784-90. doi: 10.1152/ajprenal.00455.2011. Epub 2011 Dec 21.
The renin-angiotensin system (RAS) plays an important role in renal physiology and kidney injury. Although the cellular effects of the RAS activation are generally attributed to angiotensin II (ANG II), the recent identification of angiotensin-converting enzyme 2 has shifted the focus to other peptides including Ang-(1-7). The G protein-coupled receptor for Ang-(1-7), mas, is expressed by mesangial cells (MC) but the signal transduction pathways activated by Ang-(1-7) in MC have not been fully elucidated. Accordingly, we studied the effect of Ang-(1-7) on extracellular signal-related kinase (ERK)1/2 activation in rat MC. Ang-(1-7)-induced ERK1/2 phosphorylation in MC is time- and concentration-dependent. Pretreatment of MC with the mas receptor antagonist A-779 but not the AT(1) antagonist losartan or the AT(2) antagonist PD123319 abrogated ERK1/2 activation. Neither pretreatment with the NADPH oxidase inhibitors diphenyleneiodonium and apocynin nor pretreatment with the epidermal growth factor (EGF) receptor antagonists AG1478 and PD158780 attenuated Ang-(1-7)-induced activation of ERK1/2. Even though each of these compounds abolished ANG II-induced activation of ERK1/2. Ang-(1-7) increased intracellular cAMP levels and activated protein kinase A (PKA) and inhibition of either adenylyl cyclase or PKA activity attenuated Ang-(1-7)-induced ERK1/2 activation. In conclusion, Ang-(1-7)-induced activation of ERK1/2 is cAMP/PKA-dependent in MC, but independent of NADPH oxidase and the EGF receptor.
肾素-血管紧张素系统(RAS)在肾脏生理学和肾损伤中起着重要作用。尽管 RAS 激活的细胞效应通常归因于血管紧张素 II(ANG II),但最近发现的血管紧张素转换酶 2 已将焦点转移到包括 Ang-(1-7)在内的其他肽。Ang-(1-7)的 G 蛋白偶联受体 mas 由系膜细胞(MC)表达,但 Ang-(1-7)在 MC 中激活的信号转导途径尚未完全阐明。因此,我们研究了 Ang-(1-7)对大鼠 MC 细胞外信号相关激酶(ERK)1/2 激活的影响。Ang-(1-7)诱导的 MC 中 ERK1/2 磷酸化呈时间和浓度依赖性。MC 用 mas 受体拮抗剂 A-779预处理,但不是 AT(1)拮抗剂 losartan 或 AT(2)拮抗剂 PD123319 预处理,可消除 ERK1/2 激活。NADPH 氧化酶抑制剂二苯基碘和 apocynin 预处理或表皮生长因子(EGF)受体拮抗剂 AG1478 和 PD158780 预处理均不能减弱 Ang-(1-7)诱导的 ERK1/2 激活。尽管这些化合物中的每一种都消除了 ANG II 诱导的 ERK1/2 激活。Ang-(1-7)增加细胞内 cAMP 水平并激活蛋白激酶 A(PKA),抑制腺苷酸环化酶或 PKA 活性可减弱 Ang-(1-7)诱导的 ERK1/2 激活。总之,Ang-(1-7)诱导的 MC 中 ERK1/2 激活依赖于 cAMP/PKA,但独立于 NADPH 氧化酶和 EGF 受体。